Eledon Pharmaceuticals to Participate in LifeSci Partners Immunology & Inflammation Symposium
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eledon Pharmaceuticals, a clinical stage biopharmaceutical company specializing in treatments for transplant and autoimmune conditions, announced its participation in a fireside chat at the LifeSci Partners Immunology & Inflammation Symposium on May 10, 2022, at 2:00 p.m. ET. Interested individuals can register for the webcast here. A replay will later be available on the company's website.
Details
News Market Reaction – ELDN
The recorded move for ELDN in the trading session of this news was +1.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that management will participate in a fireside chat at the LifeSci Partners Immunology & Inflammation Symposium on Tuesday, May 10th at 2:00 p.m. ET.
To register in advance for the fireside chat webcast, sign up here.
A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at https://ir.eledon.com/events-and-presentations/events.
About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)
Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.